6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- manufacturers
- AMG7905
-
- $2500.00
-
2026-05-11
- CAS:1026876-55-0
- Purity:
- Supply Ability: 10g
|
| | 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- Basic information |
| | 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- Chemical Properties |
| Boiling point | 644.7±55.0 °C(Predicted) | | density | 1.345±0.06 g/cm3(Predicted) | | pka | 3.94±0.10(Predicted) |
| | 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- Usage And Synthesis |
| Description | AMG7905 is a transient receptor potential vanilloid type 1 modulator. | | Uses | AMG 7905 is a hypothermia-inducing transient receptor potential vanilloid type 1 (TRPV1) antagonist. AMG 7905 potentiates TRPV1 channels activation by protons and drives the reflectory inhibition of thermogenesis and tail-skin vasoconstriction, while potently blocking channel activation by capsaicin[1][2]. | | References | [1] Garami A, et al. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds' pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. Acta Physiol (Oxf). 2018 Jul;223(3):e13038. DOI:10.1111/apha.13038
[2] Lehto SG, et al. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther. 2008 Jul;326(1):218-29. DOI:10.1124/jpet.107.132233 |
| | 6-Benzothiazolamine, N-[6-[2-[(cyclohexylmethyl)amino]-4-(trifluoromethyl)phenyl]-4-pyrimidinyl]- Preparation Products And Raw materials |
|